Roche and Genentech have ironed out their differences and announced this morning a friendly deal in which Roche will be buying the 44 percent of Genentech it doesn't already own for $95 a share, reports Agence France-Presse. In a joint statement, Genentech CEO Art Levinson said, "We have had a highly successful partnership with Roche for more than 18 years, and we intend to pursue our shared goal of discovering medications for serious and life-threatening conditions." The deal will total $46.8 billion.
It's a Deal
Mar 12, 2009